ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months
LONDON--(BUSINESS WIRE)--ViiV HC reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months